In the open-label trial
, patients who were previously treated with or offered pirfenidone and/or nintedanib were randomized 2:1 to receive KD025 400 mg QD monotherapy or BSC.
The product received approval based on the findings of a phase three trial named NETTER-1 and also by a subset of efficacy and safety data from a single-arm, open-label trial
in The Netherlands in more than 1,200 patients with somatostatin receptor positive tumours.
The poster reported on an open-label trial
run by the Royal Free London NHS Foundation Trust at two sites in the UK and Ireland and which included data from 21 patients, five of whom were followed for twelve months.
This is a randomised open-label trial
investigating the efficacy of continuous dosing of AXL1717.
Insulin sensitivity improved in patients on Yasmin alone or Yasmin plus metformin but significantly worsened with Yasmin plus cyproterone acetate in the open-label trial
From 24 to 56 weeks, there was an open-label trial
consisting of three injection cycles of the study drug, Dr.
The data he presented at EULAR concerned 219 patients who completed a new 9-month follow-on open-label trial
of the same group, during which all patients took the modified-release formulation.
The multicenter, open-label trial
is sponsored by Merck and is part of the VANTAGE (Vorinostat Clinical Trials in Hematologic and Solid Malignancies) program.
Seven hundred and seventy-three people completed the open-label trial
, which concluded that Seditol provides relaxation, promotes restful sleep and helps reduce fatigue due to lack of sleep.
The twelve-month, open-label trial
demonstrated that NEXIUM effectively maintains basal acid output control in this patient population.
The Juvederm experience trial is a multi-center, open-label trial
, designed to gain relevant information on physicians' use of Juvederm and Juvederm Ultra Plus and evaluate the persistence of and patient satisfaction with the products in daily clinical practice.
Investigators who studied this medication last year in a preliminary open-label trial
in people with relapsing-remitting MS reported that it achieved a reduction in disease activity as measured by MRI.